Cargando…

Clinical Experience with Ropeginterferon Alfa-2b in the Off-Label Use for the Treatment of COVID-19 Patients in Taiwan

INTRODUCTION: This study, for the first time to our knowledge, evaluated the efficacy of ropeginterferon alfa-2b, a long-acting pegylated interferon (IFN)-alfa, in the treatment of COVID-19. METHODS: We retrospectively evaluated ropeginterferon alfa-2b administered subcutaneously at a single dose of...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Kuan-Yuan, Lee, Kang-Yun, Qin, Albert, Luo, Ching-Shan, Yeh, Yun-Kai, Zheng, Jing-Quan, Chen, Ching-Mei, Tsai, Chan-Yen, Lin, Sheena, Liao, Jason, Huang, Yi-Wen, Feng, Po-Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672342/
https://www.ncbi.nlm.nih.gov/pubmed/34910280
http://dx.doi.org/10.1007/s12325-021-01998-y